An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Naltrexone (Primary) ; Buprenorphine/naloxone
- Indications Opioid abuse
- Focus Therapeutic Use
- Acronyms BUP/NXT-VIVI
- 04 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Oct 2014 Planned End Date changed from 1 Sep 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 26 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.